Palliative Care News

Medical cannabis can safely help alleviate cancer-related pain while reducing the medication burden for patients with cancer, according to a study published in BMJ Supportive & Palliative Care.

Medicaid expansion under the Affordable Care Act appeared associated with an increase in use of palliative care by individuals with newly diagnosed stage IV cancers, according to data published in Health Affairs.

Patients with cancer who took part in advance care planning tended to have less aggressive and more comfort-based end-of-life care than those who did not, according to a study conducted by researchers at Regenstrief Institute.

CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.

Bereaved parents prioritized satisfactory symptom management above all other aspects of end-of-life care for their children who died of cancer, study results showed.

Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs. intravenously, U.S. facilities appear to underuse this delivery method, according to a research letter published in JAMA Oncology.

Palliative care specialist services provided around the time of cancer surgery with curative intent failed to significantly improve patient outcomes, results of a randomized study showed.

Oncology drug costs overall, and immunotherapy costs specifically, drove Medicare spending increases for outpatient end-of-life cancer care, according to research in International Journal of Radiation Oncology, Biology, Physics.

Nurse-led primary palliative care led to significantly higher uptake of advance care planning vs. standard care among patients with advanced cancers, according to study results in JCCN — Journal of the National Comprehensive Cancer Network.

Increased awareness of the quality-of-life harm and financial burden associated with continued cancer treatment at the end of a patient’s life has led professional societies to promote reduced systemic anticancer therapy at this stage.